safinamide has been researched along with oxymetazoline in 1 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (oxymetazoline) | Trials (oxymetazoline) | Recent Studies (post-2010) (oxymetazoline) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 738 | 128 | 159 |
| Protein | Taxonomy | safinamide (IC50) | oxymetazoline (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.578 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 3.261 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 1.332 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.2 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.273 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 2.633 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0056 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 2.844 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.285 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.578 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0056 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.056 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.67 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowles, K; Bradshaw, A; Meosky, K; Mospan, C; Mospan, G; Vance, S | 1 |
1 other study(ies) available for safinamide and oxymetazoline
| Article | Year |
|---|---|
Drug updates and approvals: 2017 in review.
Topics: Adamantane; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Benzylamines; Dipeptides; Drug Approval; Drug Combinations; Glucosides; Humans; Oxymetazoline; Primary Health Care; United States; United States Food and Drug Administration | 2017 |